https://cms.megaphone.fm/channel/NPTNI2342831792 en Copyright 2026 Inception Point AI Discover how GLP-1 drugs—famous for weight loss—are revolutionizing kidney disease treatment. Host Julia Cartwright breaks down landmark trials, protective mechanisms, and real-world access gaps, revealing why these medications may be the most important kidney breakthrough in decades. Each episode stands alone. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI. https://megaphone.imgix.net/podcasts/8b332518-4d9b-11f1-8d36-cf928eebe3eb/image/59cc3cd24223a452561a53d6f8151e2a.jpg?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress https://cms.megaphone.fm/channel/NPTNI2342831792 no episodic Inception Point AI Discover how GLP-1 drugs—famous for weight loss—are revolutionizing kidney disease treatment. Host Julia Cartwright breaks down landmark trials, protective mechanisms, and real-world access gaps, revealing why these medications may be the most important kidney breakthrough in decades. Each episode stands alone. For more content like this, visit QuietPlease.ai This content was created in partnership and with the help of Artificial Intelligence AI. Quiet. Please info@inceptionpoint.ai https://player.megaphone.fm/NPTNI2555482538 Join host Julia Cartwright as she uncovers the surprising kidney-protecting powers of GLP-1 drugs—those medications you know for blood sugar control and weight loss. Through groundbreaking trial data and expert insights, discover how these drugs shield kidney tissue, who benefits most, and the critical access gaps leaving patients behind. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:40:02 -0000 trailer Inception Point AI Join host Julia Cartwright as she uncovers the surprising kidney-protecting powers of GLP-1 drugs—those medications you know for blood sugar control and weight loss. Through groundbreaking trial data and expert insights, discover how these drugs shield kidney tissue, who benefits most, and the critical access gaps leaving patients behind. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 35 https://player.megaphone.fm/NPTNI9780232401 Host Julia Cartwright examines who benefits most from GLP-1 drugs for kidney protection in type 2 diabetes and chronic kidney disease. Drawing on the FLOW trial, Lancet meta-analyses, and Vanderbilt genetic research, she explores prescription gaps preventing high-risk patients from accessing these therapies and discusses emerging evidence for non-diabetic populations with obesity-related kidney disease. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:40:00 -0000 full Inception Point AI Host Julia Cartwright examines who benefits most from GLP-1 drugs for kidney protection in type 2 diabetes and chronic kidney disease. Drawing on the FLOW trial, Lancet meta-analyses, and Vanderbilt genetic research, she explores prescription gaps preventing high-risk patients from accessing these therapies and discusses emerging evidence for non-diabetic populations with obesity-related kidney disease. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1453 https://player.megaphone.fm/NPTNI4761595900 Join host Julia Cartwright as she explores how GLP-1 drugs like semaglutide—originally designed for diabetes—became powerful kidney protectors. Through clinical trials and genetic studies, Julia unpacks the dual-channel protection these medications offer: systemic effects like blood sugar control and direct tissue-level defense against fibrosis and inflammation. Discover why this discovery is reshaping kidney disease treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:39:56 -0000 full Inception Point AI Join host Julia Cartwright as she explores how GLP-1 drugs like semaglutide—originally designed for diabetes—became powerful kidney protectors. Through clinical trials and genetic studies, Julia unpacks the dual-channel protection these medications offer: systemic effects like blood sugar control and direct tissue-level defense against fibrosis and inflammation. Discover why this discovery is reshaping kidney disease treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1680 https://player.megaphone.fm/NPTNI7514688501 Julia Cartwright examines how the groundbreaking FLOW trial revealed GLP-1 drugs like semaglutide reduce chronic kidney disease progression by 24% in diabetic patients—a finding so significant the study was stopped early, reshaping treatment for millions facing kidney failure. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. Tue, 07 Apr 2026 02:39:50 -0000 full Inception Point AI Julia Cartwright examines how the groundbreaking FLOW trial revealed GLP-1 drugs like semaglutide reduce chronic kidney disease progression by 24% in diabetic patients—a finding so significant the study was stopped early, reshaping treatment for millions facing kidney failure. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI. 1532